NICE does not recommend Vidaza (azacitidine) to treat acute myeloid leukaemia- Celgene
The National Institute for Health and Care Excellence (NICE) in preliminary guidance does not recommend Vidaza (azacitidine) from Celgene as a treatment for acute myeloid leukaemia in patients with more than 30% leukaemic bone marrow blasts, where those patients are aged 65 or older and who are not eligible for haematopoietic stem cell transplantation.
NICE considered that there was a high degree of uncertainty about the effectiveness of the drug relative to current conventional chemotherapy treatments for the condition.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins